• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
    • Overview
    • Distribution by PR Newswire
    • Cision Communications Cloud®
    • Cision IR
    • Sponsored Placement
    • All Products
  • Contact
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Sponsored Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Cancer Monoclonal Antibodies Market to 2015


News provided by

Reportlinker

Mar 14, 2012, 07:13 ET

Share this article

Share this article


NEW YORK, March 14, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Cancer Monoclonal Antibodies Market to 2015

http://www.reportlinker.com/p0795425/Cancer-Monoclonal-Antibodies-Market-to-2015.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

Globally, cancer is one of the leading causes of death, and accounted for almost 13% of total deaths in 2008. The cases of lung and breast cancers are expected to grow rapidly in the coming years. In order to treat the life-threatening disease more efficiently and with enhanced specificity, monoclonal antibodies have become the most widely used cancer therapy. As per the findings of our new research report, cancer monoclonal antibodies provide high specificity to treat tumors and several formats exist for the types of cancer monoclonal antibodies available.

According to "Cancer Monoclonal Antibodies Market to 2015", cancer monoclonal antibodies have evolved greatly from the first time they were implemented, and have created a strong demand since then. In the recent time, some very important monoclonal antibodies, such as Yervoy (ipilimumab) have entered the market. Our study expects that these antibodies will consume the share of leading monoclonal antibody products in the coming years.

Our research observed that the strong demand for effective cancer treatments and high prevalence are driving the cancer monoclonal antibodies market which is anticipated to grow at a CAGR of around 7% during 2012-2015. While research and innovation in this field have been growing exorbitantly, the industry has witnessed a large number of consolidation activities. In the report, we have also studied how technological advancements and a subsequent increase in number of approvals are influencing the market growth.

During the study of latest industry trends and drivers, we observed that conjugated cancer antibody therapies offer efficient cancer treatments. Besides, bispecific antibodies (BiAbs) present a unique opportunity to redirect immune effector cells to kill cancer cells. Our report covers the analysis of the entire monoclonal antibody market for cancer, and presents market forecasts for leading products. The geographic analyses for key markets, carried out in the research, foresee that the US and Europe will continue holding significant market shares, andJapan will exhibit unaltered double digit growth.

In our research report, we have conducted a comprehensive pipeline analysis of the expected cancer monoclonal antibodies and their phase of development. We found that maximum products are expected in the field of breast cancer in near future. The study discusses in detail the key market players, their business activities, key monoclonal antibody products which are available in the market and in pipeline. Overall, we expect the cancer monoclonal antibody market to show stupendous growth and great evolution in the coming years.

1. Analyst View2. Research Methodology3. The Global Burden of Cancer3.1 Cancer - A Leading Cause of Death3.2 Current and Future Cancer Cases: By Type and Geography3.3 Common Causes of Cancer4. Global Cancer Market Outlook to 20154.1 Current and Future Growth4.2 Analysis by Therapeutic Areas5. Monoclonal Antibodies: Introduction and Working5.1 Types of Mabs5.1.1 Murine Antibodies5.1.2 Chimeric and Humanized Antibodies5.1.3 Fully Human Antibodies5.2 Conjugated Cancer Therapies using MAbs5.2.1 Radioimmunotherapy5.2.2 Antibody-directed Enzyme Pro-drug Therapy (ADEPT)5.2.3 Immunoliposomes5.2.4 Immunotoxin5.2.5 Immunocytokine5.3 mAb Therapies5.3.1 Avastin/Bevacizumab5.3.2 Rituxan/Rituximab5.3.3 Herceptin/Trastuzumab5.3.4 Erbitux/Cetuximab5.3.5 Vectibix/Panitumumab5.3.6 Campath/Alemtuzumab5.3.7 Zevalin/ Ibritumomab5.3.8 Bexxar/Tositumomab5.3.9 Arzerra/Ofatumumab6. Industry Trends and Drivers6.1 Strategic Activity Building Up in the Market6.2 New Approvals Showing Promising Future6.3 Bispecific Antibodies: Emerging Therapeutic Treatment6.4 Japan Gearing-up for Cancer Antibodies7. Global Anti-Neoplastic mAbs Market Outlook to 20157.1 Market Size7.2 Anti-Neoplastic mAbs: Approval History and Market Share7.3 Anti-Neoplastic mAbs: Current and Future Market Size7.3.1 Avastin (Bevacizumab)7.3.2 MabThera/Rituxan (Rituximab)7.3.3 Herceptin (Trastuzumab)7.3.4 Erbitux (Cetuximab)7.3.5 Vectibix (Panitumumab)7.4 Country-Level Analysis7.4.1 US7.4.2 Japan7.4.3 Europe7.5 Market Share of Key Players8. Pipeline Analysis for Anti-Neoplastic Monoclonal Antibodies9. Competitive Landscape9.1 Roche9.2 Immunomedics9.3 Bristol-Myers Squibb9.4 AstraZeneca9.5 Eli Lilly9.6 Amgen

List of Figures:

Figure 3-1: Global - Leading Causes of Non-Communicable Deaths (%), 2008Figure 3-2: Global - Number of Cancer Deaths (Million), 2002, 2020 & 2030Figure 3-3: Global - Number of New Cancer Cases (Million), 2009 & 2020Figure 3-4: Global - New Cancer Cases by Region (%), 2009Figure 3-5: Global - Forecast for the New Cancer Cases by Region (%), 2020Figure 4-1: Global - Cancer Market (Billion US$), 2011-2015Figure 4-2: Global - Cancer Market by Player (%), 2011Figure 4-3: Global - Cancer Market by Therapeutic Segment (%), 2011Figure 5-1: Types of Monoclonal AntibodiesFigure 5-2: Hybridoma Technology for Mouse-derived Monoclonal AntibodiesFigure 7-1: Global - Anti-Neoplastic mAbs Market (Billion US$), 2011-2015Figure 7-2: Global - Anti-Neoplastic mAbs Market by Product (%), 2011Figure 7-3: Global - Avastin Sales (Billion US$), 2011-2015Figure 7-4: Global - MabThera/Rituxan Sales (Billion US$), 2011-2015Figure 7-5: Global - Herceptin Sales (Billion US$), 2011-2015Figure 7-6: Global - Erbitux Sales (Billion US$), 2011-2015Figure 7-7: Global - Vectibix Sales (Million US$), 2011-2015Figure 7-8: Global - Anti-Neoplastic mAbs Market by Country/Region (%), 2011Figure 7-9: US - Anti-Neoplastic mAbs Market (Billion US$), 2011-2015Figure 7-10: Japan - Anti-Neoplastic mAbs Market (Billion US$), 2011-2015Figure 7-11: Europe - Anti-Neoplastic mAbs Market (Billion US$), 2011-2015Figure 7-12: Global - Anti-Neoplastic mAbs Market by Player (%), 2011Figure 8-1: Global - Breakup of Anti-Neoplastic mAbs in Pipeline by Phase

List of Tables:

Table 3-1: Global - Number of New Cancer Cases by Type and Geography (2009)Table 3-2: Global - Forecast for the Number of New Cancer Cases by Type and Geography (2020)Table 4-1: Global - Revenues from Major Therapy Areas (Billion US$), 2011 & 2015Table 7-1: Global - List of FDA Approved Anti-Neoplastic mAbs with Year and IndicationTable 7-2: US - Forecast for the Number of Cancer Cases and Deaths by Types (2012)Table 7-3: US - Anti-Neoplastic mAbs Expenditure in Clinics (Million US$), 2010 & 2011Table 7-4: Japan - Number of Cancer Deaths by Type and Gender (2008 & 2009)Table 7-5: Japan - Approval Date for Key Cancer mAbsTable 7-6: EU - Number of Cancer Cases and Deaths by Type (2008)Table 7-7: EU - Approval Date for Key Cancer mAbsTable 8-1: Global - Anti-Neoplastic mAbs of Key Players in PipelineTable 8-2: Global - Anti-Neoplastic mAbs in Pipeline for Cancer Type by RankTable 9-1: Roche - Key Monoclonal Antibodies in MarketTable 9-2: Roche - Key Monoclonal Antibodies in PipelineTable 9-3: Immunomedics - Key Monoclonal Antibodies in MarketTable 9-4: Immunomedics - Key Monoclonal Antibodies in PipelineTable 9-5: Bristol-Myers Squibb - Key Monoclonal Antibodies in MarketTable 9-6: Bristol-Myers Squibb - Key Monoclonal Antibodies in PipelineTable 9-7: AstraZeneca - Key Monoclonal Antibodies in PipelineTable 9-8: Eli Lilly - Key Monoclonal Antibodies in MarketTable 9-9: Eli Lilly - Key Monoclonal Antibodies in PipelineTable 9-10: Amgen - Key Monoclonal Antibodies in MarketTable 9-11: Amgen - Key Monoclonal Antibodies in Pipeline

To order this report:Biopharmaceutical Industry: Cancer Monoclonal Antibodies Market to 2015

More  

Market Research Report

Check our  

Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Modal title

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2022 Cision US Inc.